Antiviral therapy for chronic hepatitis B

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 425-438

  Jafri, Syed Mohammed R ^a   Lok, Anna Suk Fong ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cirrhosis; Hepatitis B e antigen; Hepatitis B virus DNA; Interferon; Nucleos(t)ide analogs

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; NUCLEOSIDE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; BIRTH DEFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MITOCHONDRIAL TOXICITY; MYALGIA; MYOPATHY; MYOSITIS; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT; BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; LIVER; LIVER NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VIRUS REPLICATION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; NUCLEOSIDES; VIRUS REPLICATION;

EID: 77954643521     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.005     Document Type: Review

References (50)

1. Sorrell M.F., Belongia E.A., Costa J., et al. National institutes of health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009, 150(2):104-110.
2. Lok A.S., McMahon B.J. Chronic Hepatitis B Update 2009. AASLD Practice Guidelines. Available at:, Accessed November 25, 2009. http://www.aasld.org.
3. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
4. Fattovich G., Brollo L., Giustina G., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32:284-288.
5. Iloeje U.H., Yang H., Jen C.L., et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007, 5(8):921-931.
6. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
7. Chen Y.C., Chu C.M., Liaw Y.F. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010, 51(2):435-444.
8. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
9. European Association for the Study of the Liver EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50(2):227-242.
10. Liaw Y.F., Leung N., Kao J.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
11. Kim W.R., Terrault N.A., Pedersen R.A., et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137(5):1680-1686.
12. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136(2):477-485.
13. Yao F.Y., Terrault N.A., Freise C., et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001, 34:411-416.
14. Fontana R.J., Hann H.W., Perrillo R.P., et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002, 123:719-727.
15. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
16. Yim H.J., Lok A.S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006, 43(2 Suppl 1):S173-S181.
17. Degertekin B., Lok A.S. Indications for therapy in hepatitis B. Hepatology 2009, 49(S5):S129-S137.
18. Hui C.K., Leung N., Yuen S.T., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46(2):395-401.
19. Andreani T., Serfaty L., Mohand D., et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007, 5(5):636-641.
20. Chu C.M., Hung S.J., Lin J., et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004, 116:829-834.
21. Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36(1):186-194.
22. Wu I.C., Lai Cl, Han S.H., et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated ALT and biopsy-proven histologic damage. Hepatology 2010, 51(4):1185-1189.
23. Iloeje U.H., Yang H.I., Su J., et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
24. Manno M., Cammà C., Schepis F., et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004, 127(3):756-763.
25. Yuen M.F., Yuan H.J., Wong D.K., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54(11):1610-1614.
26. Lai M., Hyatt B.J., Nasser I., et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007, 47(6):760-767.
27. Kumar M., Sarin S.K., Hissar S., et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134(5):1376-1384.
28. The Antiretroviral Pregnancy Registry Available at:, Accessed December 10, 2009. http://www.apregistry.com.
29. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49(Suppl 5):S156-S165.
30. Lok A.S., Liang R.H., Chiu E.K., et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991, 100:182-188.
31. Seok J.I., Lee D.K., Lee C.H., et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49(6):2080-2086.
32. Kim B.K., Oh J., Kwon S.Y., et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009, 51(4):829-834.
33. Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48(3):750-758.
34. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131(6):1743-1751.
35. Avila C, Laeufle R, Bao W. CK elevation during chronic hepatitis B (CHB) treatment with telbivudine: experience from the combined globe (NV-02B-007/CLDT600A2302) and NV-02B-015(015) study clinical safety database. Presented at the 19th Asian Pacific Association for the Study of the Liver (APASL). Hong Kong, February 13-16, 2009.
36. Goncalves J., Laeufle R., Avila C. Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the Novartis global database. J Hepatol 2009, 50:S329.
37. Lange C.M., Bojunga J., Hofmann W.P., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50(6):2001-2006.
38. Hoofnagle J.H., Di Bisceglie A.M., Waggoner J.G., et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993, 104:1116-1121.
39. Perrillo R., Tamburro C., Regenstein F., et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995, 109:908-916.
40. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2A, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
41. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
42. Buster E.H., Hansen B.E., Lau G.K., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137(6):2002-2009.
43. Marcellin P., Bonino F., Lau G.K., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009, 136(7):2388.
44. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
45. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129(2):528-536.
46. Sung J.J., Lai J.Y., Zeuzem S., et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48(5):728-735.
47. Moucari R., Mackiewicz V., Lada O., et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49(4):1151-1157.
48. Brunetto M.R., Moriconi F., Bonino F., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49(4):1141-1150.
49. Fung S.K., Wong F., Hussain M., et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004, 11(5):432-438.
50. Hadziyannis S., Sevastianos V., Rapti I. Outcome of HBeAg-negative chronic hepatitis B (CHB) 5 years after discontinuation of long term adefovir dipivoxil (ADV) treatment. J Hepatol 2009, 50(S1):S9-S10.